BioCentury
ARTICLE | Company News

Shire splits neuro and rare disease businesses

January 9, 2018 11:54 PM UTC

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for its neurology franchise (see BioCentury Extra, Aug. 2, 2017).

CEO Flemming Ornskov announced the changes Monday at the J.P. Morgan Healthcare Conference in San Francisco, saying that establishing the two divisions would be the company's focus for 1H18. In August, Shire floated the possibility of spinning out the company’s neuroscience business into an independent public company...